Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) Modeling
Prediction of monoclonal antibody (mAb) pharmacokinetics (PK) in drug development remains challenging due to the lack of a standardized method for predicting elimination based on mechanistic pathways. Among the processes implemented in the physiologically based pharmacokinetic (PBPK) models for large molecules, FcRn-mediated recycling constitutes the predominant mechanism influencing the elimination of mAbs. In the present study, we assessed the predictivity of a generic value for the dissociation constant (<i>K</i>d) for FcRn (<i>K</i>d<sub>FcRn</sub>) in humans, identified based on clinical data, to provide means for mechanism-based PK projections for mAbs in first-in-human (FIH) trials. We compiled a database of digitalized linear PK profiles for 50 mAbs administered intravenously in humans. Subsequently, the database was randomly divided into a training and a test data set, using a 7:3 ratio. For each drug in the training data set, a generic PBPK model was set up in PK-Sim, and a drug-specific <i>K</i>d<sub>FcRn</sub> parameter was estimated through data fitting. The median of estimated drug-specific <i>K</i>d<sub>FcRn</sub> was 1.05 μM and was used for naïve predictions of the PK of the drugs in the test data set. Plasma exposure (AUC) and terminal half-life were accurately predicted for 80% and 60% of the drugs in the test data set, respectively, with a prediction error within the 0.80-1.25-fold range. Additionally, 100% of the test data set showed prediction errors within the 0.50-2.00-fold range for both plasma exposure and half-life. The median of the estimated drug-specific <i>K</i>d<sub>FcRn</sub> determined using the whole database with 50 mAbs was 1.07 μM and was retained after evaluation as a more accurate default <i>K</i>d<sub>FcRn</sub> value. The reported results provide a large database of mAbs PBPK models with estimated <i>K</i>d<sub>FcRn</sub> values using PK-Sim, and a validated default <i>K</i>d<sub>FcRn</sub> value of 1.07 μM to perform naïve predictions of mAbs linear PK in the context of FIH trials.
Authors
- Antoine Deslandes (ORCID: https://orcid.org/0009-0007-6272-7327)
- Donato Teutonico (ORCID: https://orcid.org/0000-0003-4931-410X)
- Salih Benamara (ORCID: https://orcid.org/0009-0007-0158-1336)
- Marylore Chenel (ORCID: https://orcid.org/0000-0001-7397-4007)
- Laurent Nguyen (ORCID: https://orcid.org/0000-0002-8560-3008)
- Erik Sjögren (ORCID: https://orcid.org/0000-0003-4318-6039)
- Florence Gattacceca
Institutions
- Aix-Marseille Université (FR)
- Quantitative BioSciences (US)
- Centre Inria d'Université Côte d'Azur (FR)
Publication Details
- Journal
- ACS Pharmacology & Translational Science
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1021/acsptsci.5c00674
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00